Immunological substance testing on human lymphatic micro-organoids in vitro

Journal of Biotechnology

Volumn 148, Issue 1, 2010, Pages 38-45

  Giese, Christoph ^a   Lubitz, Annika ^a   Demmler, Christian D ^a   Reuschel, Jana ^a   Bergner, Konstanze ^a   Marx, Uwe ^a  

^a PROBIOGEN AG   (Germany)

Author keywords

Bioreactor; Culture system; Immunogenicity; Immunotoxicity; In vitro testing; Lymph node model

Indexed keywords

BIOREACTOR CULTURES; IMMUNOGENICITY; IMMUNOTOXICITY; IN-VITRO; LYMPH NODE;

ANIMAL CELL CULTURE; ANIMALS; ANTIBODIES; BIOREACTORS; BODY FLUIDS; CELLULAR MANUFACTURING; CONSUMER PRODUCTS; DRUG INTERACTIONS; DRUG PRODUCTS; FLOW CYTOMETRY; IMMUNOLOGY; MONOLAYERS; PHYSIOLOGY; THREE DIMENSIONAL; TISSUE;

CELL CULTURE;

CYTOKINE; DEXAMETHASONE; HEPATITIS A VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOLOGIC AGENT; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE ACTIVATION; BIOLOGICAL MODEL; BIOREACTOR; CELL COMPOSITION; CELLULAR IMMUNITY; CYTOKINE RELEASE; DRUG EXPOSURE; FLOW CYTOMETRY; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; IMAGING; IN SITU IMAGING; IN VITRO STUDY; LYMPH NODE; LYMPHATIC MICROORGANOID; PLASMA CELL; PRIORITY JOURNAL; TISSUE ENGINEERING; CYTOCHEMISTRY; CYTOPLASM; DEVICES; IMMUNOLOGY; METABOLISM; PROCEDURES; SECRETION (PROCESS); TISSUE CULTURE TECHNIQUE;

BIOREACTORS; CYTOKINES; HISTOCYTOCHEMISTRY; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGLOBULIN M; LYMPH NODES; MODELS, IMMUNOLOGICAL; ORGANOIDS; TISSUE CULTURE TECHNIQUES;

ANIMALIA;

EID: 77953914684     PISSN: 01681656     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2010.03.001     Document Type: Article

References (32)

1. Allen C.D.C., Ansel K.M., Low C., Lesley R., Tamamura H., Fujii N., Cyster J.G. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat. Immunol. 2004, 5(9):943-952.
2. Allen C.D.C., Okada T., Cyster J.G. Germinal-center organization and cellular dynamics. Immunity 2007, 27(2):190-202.
3. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392(6673):245-252.
4. Basketter D.A., Evans P., Fielder R.J., Gerberick G.F., Dearmana R.J., Kimbere I. Local lymph node assay-validation, conduct and use in practice. Food Chem. Toxicol. 2002, 40:593-598.
5. Camacho S.A., Kosco-Vilbois M.H., Berek C. The dynamic structure of the germinal center. Immunol. Today 1998, 19(11):511-514.
6. Cosmetics, 7th Amendment of the Cosmetics Directive (2003/15/EC) (2003) and EU Cosmetics Directive (76/768/EEC) (1976).
7. Crivellato E., Vacca A., Ribatti D. Setting the stage: an anatomist's view of the immune system. Trends Immunol. 2004, 25(4):210-217.
8. Fleshner M., Deak T., Nguyen K.T., Watkins L.R., Maier S.F. Endogenous glucocorticoids play a positive regulatory role in the anti-keyhole limpet hemocyanin in vivo antibody response. J. Immunol. 2001, 166:3813-3819.
9. Giese C., Demmler C., Ammer R., Hartmann S., Lubitz A., Miller L., Mueller R., Marx U. A human lymph node in vitro-challenges and progress. Artif. Organs 2006, 30(10):803-808.
10. Griffith L.G., Swartz M.A. Capturing complex 3D tissue physiology in vitro. Nat. Rev. Mol. Cell Biol. 2006, 7:211-224.
11. Hartung T., Rovida C. Chemical regulators have overreached. Nature 2009, 460(7259):1080-1081.
12. Holmes A., Brown R., et al. Engineering tissue alternatives to animals: applying tissue engineering to basic research and safety testing. Regen. Med. 2009, 4(4):579-592.
13. ICH, International Conference on Harmonisation of Technical Requirements for Registration of Pharamceuticals for Human Use, ICH Harmonised Tripartite Guideline (ICH) Safety and Efficacy Guidelines (). http://www.ich.org/.
14. ISO, 1999 ISO 10993-5, International Standards Organization Biological Evaluation for Medical Devices. Part 5. Tests for In Vitro Cytotoxicity 1999, Geneva.
15. Junt T., Scandella E., Ludewig B. Form follows function: lymphoid tissue microarchitecture in antimicrobial immune defence. Nat. Rev. Immunol. 2008, 8(10):764-775.
16. Kimber I., Pichowski J.S., Betta C.J., Cumberbatch M., Basketter D.A., Dearman R.J. Session 2: immunotoxicity and allergy alternative approaches to the identification and characterization of chemical allergens. Toxicol. In Vitro 2001, 15:307-312.
17. Lindhout E., De Groot C., Koopman G. Triple check for antigen specificity of B cells during germinal centre reactions. Immunol. Today 1997, 18(12):573-577.
18. Lutolf M.P., Hubbell J.A. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat. Biotechnol. 2005, 23(1):47-55.
19. Mueller S.N., Germain R.N. Stromal cell contributions to the homeostasis and functionality of the immune system. Nat. Rev. Immunol. 2009, 9(9):618-629.
20. Nyhus J., Kran A.M.B., Sommerfelt M.A., Baksaas I., Sørensen B., Kvale D. Multiple antigen concentrations in delayed-type hypersensitivity (DTH) and response diversity during and after immunization with a peptide-based HIV-1 immunotherapy candidate (Vacc-4x). Vaccine 2006, 24:1543-1550.
21. Pörtner R., Giese C. An Overview on Bioreactor Design, Prototyping and Process Control for Reproducible Three-Dimensional Tissue Culture. Drug Testing In Vitro: Breakthroughs and Trends in Cell Culture Technology. Drug Testing In Vitro: Breakthroughs and Trends in Cell Culture Technology 2007, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, pp. 53-78.
22. REACH, Registration, Evaluation, Authorisation and Restriction of Chemical Substances According to the European Community Regulation on Chemicals (EC 1907/2006).
23. Sakuma S., Kato Y., Nishigaki F., Magari K., Miyata S., Ohkubo Y., Goto T. Effects of FK506 and other immunosuppressive anti-rheumatic agents on T cell activation mediated IL-6 and IgM production in vitro. Int. Immunopharmacol. 2001, 1.749-1.757.
24. Sallusto F., Cella M., Danieli C., Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 1995, 182:389-400.
25. Salomonsson S., Jonsson M.V., Skarstein K., Brokstad K.A., Hjelmstrom P., Wahren-Herlenius M., Jonsson R. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren's syndrome. Arthritis Rheum. 2003, 48(11):3187-3201.
26. Schraven B., Kalinke U. CD28 superagonists: what makes the difference in humans?. Immunity 2008, 28(5):591-595.
27. Stebbings R., Findlay L., Edwards C., Eastwood D., Bird C., North D., Mistry Y., Dilger P., Liefooghe E., Cludts I., Fox B., Tarrant G., Robinson J., Meager T., Dolman C., Thorpe S.J., Bristow A., Wadhwa M., Thorpe R., Poole S. " Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J. Immunol. 2007, 179(5):3325-3331.
28. Suematsu S., Watanabe T. Generation of a synthetic lymphoid tissue-like organoid in mice. Nat. Biotechnol. 2004, 22(12):1539-1545.
29. Suntharalingam G., Perry M.R., Ward S., Brett S.J., Castello-Cortes A., Brunner M.D., Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 2006, 355:1018-1028.
30. Torres K.C.L., Antonelli L.R.V., Souza A.L.S., Teixeira M.M., Dutra W.O., Gollob K.J. Norepinephrine, dopamine and dexamethasone modulate discrete leukocyte subpopulations and cytokine profiles from human PBMC. J. Neuroimmunol. 2005, 166:144-157.
31. von Andrian U.H., Mempel T.R. Homing and cellular traffic in lymph nodes. Nat. Rev. Immunol. 2003, 3:867-878.
32. Westmoreland C., Holmes A.M. Assuring consumer safety without animals-applications for tissue engineering. Organogenesis 2009, 5(2):67-72.